Magic mushrooms again? study tests second retreat for cancer anxiety
NCT ID NCT06644170
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 1 trial tested whether a second psilocybin-assisted group therapy retreat is safe and helpful for anxiety in 15 patients with metastatic cancer who had only a partial response to their first retreat. Psilocybin, the active ingredient in magic mushrooms, is given in a group therapy setting to change thinking patterns and reduce anxiety. The study focused on safety and side effects, while also measuring changes in anxiety and depression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
psilocybin (magic mushroom extract)
What this could lead to
If it works, this could offer a way to ease anxiety and distress in cancer patients who didn't fully benefit from a first psychedelic retreat.
What could go wrong
This is a very small, early-phase trial with only 15 participants, so results may not apply widely. Psilocybin can cause intense mood changes and anxiety during the session.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHATIC SYSTEM NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States